New UK Site Management Organization Open for Business with New Northern England Investigator Site

Site Management Organization (Panthera Biopartners)[1] launched its first clinical trials site in the UK.  Based in Preston, in northern England, the new clinical investigational site is open for studies—independent Panthera Biopartners (Panthera) has three clinical trials already in the pipeline.

Panthera Biopartners Background

Founded by Dr. Ian Smith[2], founder of Synexus (the world’s largest SMO) in December 2018[3], he is one of the co-founders of the independently controlled SMO Panthera. The other co-founder is Professor John Lyon[4], who was previously a global executive at CRO Covance. The company is presently working on raising an “A” round of financing which they report in a press release will be concluded shortly. The SMO is presently recruiting a CEO.

The First Site

The first Panthera clinical investigational site is based in Preston, Lancashire, UK in October, 2019. More sites are planned in Glasgow and Rochdale in early 2020 with further sites under negotiation.       

SMO Focus Area

SMO will expand its network of clinical investigational sites with the aim of recruiting patients and running clinical trials in therapy areas which are traditionally managed in primary care including cardiac disease, allergies, migraine, osteoarthritis, osteoporosis and diabetes. Additionally the company will expand into NASH, Neurology and Oncology into the new year.

Study Start up Expertise

The SMO brings considerable expertise in important areas such as study start up and site activation cycle times. For example, founding team members (and management) has extensive experience in patient recruitment and the conduct of clinical trials.

Call to Action: Interested in clinical investigational sites in the UK—connect with Panthera Biopartners.


  1. ^ (Panthera Biopartners) (
  2. ^ Dr. Ian Smith (
  3. ^ in December 2018 (
  4. ^ Professor John Lyon (

Source URL: Read More
The public content above was dynamically discovered, by graded relevancy to this keyword domain, and was specifically filtered by “Creative Commons“ re-use licensing and/or by Press Release distributions. “Source URL” states the content’s owner and/or publisher. This site references the content above to generate its value-add, the dynamic sentimental analysis below, which allows us to research global sentiments across a multitude of topics related to this site’s specific keyword domain. Additionally, where applicable, this site references the content above to provide on-demand translations and to power its “Read Article to Me” feature, which reads the content aloud to visitors. Views expressed in the content above are solely those of the authors. We take content ownerships seriously: Click “DMCA” in site footer to request applicable content take-down.

1 2